Introduction

Wegovy (semaglutide) has revolutionized obesity treatment as the first FDA-approved weekly injectable medication specifically for chronic weight management. Approved in 2021, Wegovy helps users lose 15-16% of their body weight on average—rivaling bariatric surgery results. This guide explains how Wegovy works, its clinical benefits, and why it’s a top choice for sustainable weight loss.

What Is Wegovy?

Wegovy is a GLP-1 receptor agonist containing semaglutide, a hormone-mimicking drug that regulates appetite and digestion. Unlike Ozempic (its diabetes-focused counterpart), Wegovy is prescribed exclusively for obesity in patients with:
– BMI ≥30 (obesity)
– BMI ≥27 (overweight) + weight-related conditions (e.g., hypertension, diabetes)

How Wegovy Drives Weight Loss

1. Appetite Suppression: Targets brain receptors to reduce hunger and cravings.
2. Slowed Gastric Emptying: Keeps you fuller longer, cutting calorie intake.
3. Metabolic Boost: Improves insulin sensitivity to reduce fat storage.

In the “STEP trials”, participants lost 15-16% body weight—equivalent to 34 lbs for a 225-lb individual.

Dosage and Side Effects

– Dosing: Start at 0.25 mg/week, escalating every 4 weeks to a 2.4 mg maintenance dose.

– Common Side Effects: Nausea, diarrhea, constipation (often mild and temporary).

– Serious Risks: Rare pancreatitis or gallbladder issues.

Wegovy vs Alternatives

– Ozempic: Same drug (semaglutide) but lower max dose (2 mg vs. Wegovy’s 2.4 mg).
– Mounjaro (tirzepatide): Dual GIP/GLP-1 agonist with **20-22% weight loss** but higher cost.

Wegovy balances efficacy, insurance coverage, and tolerability, making it a preferred first-line option.

Conclusion

Wegovy’s proven 15-16% weight loss, paired with its weekly dosing and strong clinical backing, makes it a leader in obesity treatment. Consult a doctor to see if Wegovy aligns with your health